Join Dr Torben Larsen for a discussion of his comprehensive paper: Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
You can recap the learnings of this journal club by reading the short, comprehensive highlights report which details the key findings of the discussion.
Access highlights report
Aalborg University Hospital
Despite the wealth of evidence demonstrating their ability to save lives, oral anticoagulants – including both warfarin and NOACs – are often avoided by clinicians, owing to the fear of iatrogenic internal bleeding. However, does this actually happen? This study of patient outcomes in a real-world setting demonstrates that not only do NOACs reduce the risk of stroke, some also feature significantly lower risks of death and major bleeding compared to warfarin.
View abstract Access full paper
This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.
After participating in this educational activity, participants will be able to:
- Describe real-world safety and efficacy data for oral anticoagulants in patients with atrial fibrillation
Prof John Camm:
- Advisor for: Boehringer Ingelheim, Daiichi Sankyo
- Consultant (retained) for: Boehringer Ingelheim
- Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer
Prof Torben Larsen:
- On speakers Bureau for: Bayer, BMS-Pfizer, Roche Diagnostics, Boehringer Ingelheim, MSD, AstraZeneca, Takeda Pharma
- Dr Larsen’s institution has received honoraria from: Janssen Scientific Affairs, LLC, Boehringer Ingelheim
Staff and reviewer disclosures
PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme.
The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.